31 results on '"Kreisel FH"'
Search Results
2. Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
- Author
-
Lee YS, Liu J, Fricano KA, Webb EM, Toolsie DR, Jones S, Rhoads JA, Vij R, Cashen AF, Abboud CN, Westervelt P, Bartlett NL, Dipersio JF, Kreisel FH, and Lim KH
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse mortality, Lymphoma, Large B-Cell, Diffuse therapy, Male, Middle Aged, Mutation, Prognosis, Salvage Therapy, Survival Analysis, Transplantation, Autologous, Young Adult, Lymphoma, Large B-Cell, Diffuse genetics, Myeloid Differentiation Factor 88 genetics, Stem Cell Transplantation methods
- Abstract
Cell-of-origin determination has emerged as an important prognostic factor for patients initially diagnosed with diffuse large B cell lymphoma (DLBCL). Specifically, the nongerminal center B cell-like (non-GCB) subtype, composed predominantly of the activated B cell-like (ABC) molecular subtype, has been shown to portend poor prognosis because of its more aggressive nature and resistance to standard cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone (CHOP)-like chemotherapy compared with the GCB subtype. The recurrent MyD88 L265P mutation, present in 29% of ABC DLBCL, was reported as an independent poor prognostic factor for patients with newly diagnosed DLBCL. For patients whose disease relapses or is refractory to first-line chemotherapy, high-dose chemotherapy with autologous stem cell transplantation (ASCT) is frequently offered as salvage therapy. However, the impact of MyD88 mutation status on post-ASCT outcome has not been reported. Here, we retrospectively analyzed, with up to 20 years of follow-up, 165 patients who underwent ASCT for relapsed/refractory DLBCL at our institution. We found that MyD88 mutation status did not correlate with overall survival (OS), post-ASCT OS, or progression-free survival (PFS). Patients with non-GCB subtype had significantly worse OS from initial diagnosis and after ASCT. Notably, high International Prognostic Index score was predictive of poor pre- and post-transplant PFS and post-transplant OS., (Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
3. CD4-positive diffuse large B-cell lymphoma: A variant with aggressive clinical potential.
- Author
-
Hussaini MO, Kreisel FH, Hassan A, Nguyen TT, and Frater JL
- Abstract
CD4 expression is rare in diffuse large B-cell lymphoma (DLBCL), with 4 previously reported cases. Its significance is uncertain. We report five patients with CD4(+) DLBCL and one CD4(+) primary mediastinal large B-cell lymphoma. Cases were identified by searching the electronic database of the department; each was reviewed. Average age was 56 years. Neoplastic cells expressed CD20 (5/6 tested cases). BCL2/BCL6 expression were seen in 3/3 tested cases, suggesting a germinal center origin. Additionally, expression of T-cell antigens CD2 and CD5 was noted in 2/2 and CD7 in 1/1 tested case. CD3 was negative in all. Lymph nodes were commonly involved (67%). Patients received chemotherapy +/- radiation (6/6) and bone marrow transplant (2/6). Average survival was 44.2 mo. CD4 expression in DLBCL raises questions of lineage commitment. CD4(+) DLBCL is rare; care should be exercised not to diagnose these as T-cell lymphomas. A subset behaves aggressively., Competing Interests: Conflict-of-interest statement: The authors declare that they have no conflict of interest.
- Published
- 2016
- Full Text
- View/download PDF
4. Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome.
- Author
-
Nguyen TT, Frater JL, Klein J, Chen L, Bartlett NL, Foyil KV, and Kreisel FH
- Subjects
- Adult, Aged, Female, Hodgkin Disease diagnosis, Hodgkin Disease pathology, Humans, Immunohistochemistry, Male, Middle Aged, Prognosis, T-Cell Intracellular Antigen-1, Tissue Array Analysis, Hodgkin Disease metabolism, PAX5 Transcription Factor metabolism, Poly(A)-Binding Proteins metabolism
- Abstract
Although the expression of T-cell antigens and proteins associated with tumor-infiltrating T-lymphocytes (TILs), regulatory T cells (T-regs), and B-cell development have been evaluated in classical Hodgkin lymphoma (cHL), few studies correlate these proteins' expression patterns with clinical outcome. The purpose of this study was to evaluate proteins expressed in the Reed-Sternberg cells (RSCs) and TILs of cHLs at initial diagnosis to determine their prognostic significance. The expression of 12 proteins in RSCs and TILs from 88 diagnostic cHL biopsies was quantitated and correlated to overall survival (OS) and progression-free survival (PFS). CD2, CD3, CD4, CD5, CD7, CD25, PD1, TIA1, MUM1, and ZAP70 expression in RSCs did not correlate with OS or PFS, nor did programmed death 1 (PD1) expression in TILs. High numbers of TIA1-positive TILs (≥50%) correlated with OS (P=0.027), but not PFS (P=0.993) in univariate analysis. Expression of CD2, CD3, CD4, CD5, and/or TIA1 (6%) in RSCs was associated with lymphocyte-rich/mixed-cellularity subtype (P=0.032). High International Prognostic Score (IPS; P=0.036), and high stage (P=0.046) were independent predictors of worse PFS in univariate analysis. Low IPS (P=0.003) and nodular sclerosing subtype (P=0.022) were associated with better OS in univariate analysis. Only the IPS predicted OS in multivariate (P=0.009) analysis. High TIA1+ TILs correlated with worse clinical outcomes for cHLs, as did PAX5-RSCs (P=0.024), although only 2/74 cases were shown to be negative for this marker, suggesting that the tumor microenvironment and a transcription factor crucial for B-cell development are critical biological determinants of the disease course.
- Published
- 2016
- Full Text
- View/download PDF
5. Hematolymphoid Lesions of the Sinonasal Tract.
- Author
-
Kreisel FH
- Subjects
- Humans, Histiocytosis, Sinus pathology, Lymphoma, Non-Hodgkin pathology, Nose Diseases pathology, Paranasal Sinus Neoplasms pathology, Plasmacytoma pathology
- Abstract
Hematolymphoid neoplasms of the sinonasal tract are rare and the majority represents non-Hodgkin lymphomas. This review will focus on morphologic, immunophenotypic, and genetic characteristics of the most common types of non-Hodgkin lymphoma, namely diffuse large B cell lymphoma and extranodal natural killer/T-cell lymphoma, nasal type, but also include the discussion of less frequent other hematolymphoid entities, such as extranodal plasmacytomas and Rosai-Dorfman disease.
- Published
- 2016
- Full Text
- View/download PDF
6. T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement.
- Author
-
Hsi AC, Robirds DH, Luo J, Kreisel FH, Frater JL, and Nguyen TT
- Subjects
- Aged, Aged, 80 and over, Biomarkers, Tumor analysis, Biopsy, Female, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Humans, Immunophenotyping, In Situ Hybridization, Fluorescence, Kaplan-Meier Estimate, Karyotyping, Leukemia, Prolymphocytic, T-Cell immunology, Leukemia, Prolymphocytic, T-Cell mortality, Leukemia, Prolymphocytic, T-Cell pathology, Male, Middle Aged, Missouri, Phenotype, Predictive Value of Tests, Prognosis, Retrospective Studies, Skin Neoplasms immunology, Skin Neoplasms mortality, Skin Neoplasms pathology, Time Factors, Ataxia Telangiectasia Mutated Proteins genetics, Biomarkers, Tumor genetics, Gene Rearrangement, Leukemia, Prolymphocytic, T-Cell genetics, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-myc genetics, Skin Neoplasms genetics
- Abstract
T-cell prolymphocytic leukemia (T-PLL) is a rare aggressive mature T-cell leukemia with frequent cutaneous presentation, which has not been well characterized. Among the 25 T-PLLs diagnosed between 1990 and 2013 at our institution, 32% (8/25) showed cutaneous manifestations, presenting as rash, purpura, papules, and ulcers. The skin biopsies showed leukemia cutis with perivascular and periadnexal irregular, small to medium-sized lymphoid infiltrates without epidermotropism. The lymphoid infiltrates were composed of mature CD4+ T cells expressing other T-cell antigens, and a subset (48%) showed dual CD4+/CD8+ coexpression. Higher median absolute peripheral blood lymphocyte count (43.0 vs. 13.0 k/mm; P=0.031) and elevated lactate dehydrogenase levels (P=0.00018) at the time of diagnosis were significantly associated with T-PLLs with skin involvement compared with those without. The extent of bone marrow involvement (P=0.849) and overall survival (P=0.144) was similar in the 2 groups. Fluorescence in situ hybridization or karyotype revealed frequent gains of MYC (67%; n=9), loss of ATM (64%; n=11), and TCL1A rearrangement or inversion 14q (75%; n=12). Gains of TCL1A was also seen (78%; n=9), including in some cases that had concurrent TCL1A rearrangement, whereas TP53 loss was less common (30%; n=10). No correlation was seen between the immunophenotype and morphology versus the presence or absence of skin involvement. These data suggest that cutaneous involvement by T-PLL is relatively common and often associated with significant peripheral blood involvement. The frequent MYC, ATM, and TCL1A alterations identified support that these genes are integral to the pathogenesis of T-PLL.
- Published
- 2014
- Full Text
- View/download PDF
7. Mast cell leukemia with prolonged survival on PKC412/midostaurin.
- Author
-
Xu X, Kreisel FH, Frater JL, and Hassan A
- Subjects
- Aged, Clinical Trials, Phase II as Topic, Female, Humans, Staurosporine therapeutic use, Antineoplastic Agents therapeutic use, Leukemia, Mast-Cell drug therapy, Leukemia, Mast-Cell pathology, Staurosporine analogs & derivatives
- Abstract
Mast cell leukemia (MCL) is a rare and aggressive form of systemic mastocytosis. There are approximately 50 reported cases since 1950s. MCL is refractory to cytoreduction chemotherapy and the average survival is only six months. We report a MCL case in a 71 year-old woman with high tumor load at the initial presentation in 2005, who did not respond to either interleukin-2 or dasatinib therapy. After enrolled in a clinical trial of PKC412 (or Midostaurin) with a daily dose of 100 mg, the patient responded well to PKC412 and became transfusion independent in three months. Since then, her disease had been stably controlled. This is the first report of a high-tumor-load MCL case which achieved prolonged survival (101 months) by PKC 412. The 101-month overall survival is the longest among reported MCL cases in the English literature.
- Published
- 2014
8. Clinicopathologic features of adult T-cell leukemias/lymphomas at a North American tertiary care medical center: infrequent involvement of the central nervous system.
- Author
-
Hsi AC, Kreisel FH, Frater JL, and Nguyen TT
- Subjects
- Adult, Aged, Biomarkers, Tumor analysis, Biomarkers, Tumor genetics, Central Nervous System Neoplasms chemistry, Central Nervous System Neoplasms genetics, Central Nervous System Neoplasms therapy, Central Nervous System Neoplasms virology, Early Detection of Cancer, Fatal Outcome, Female, Gene Rearrangement, Genes, T-Cell Receptor gamma, HTLV-I Infections complications, HTLV-I Infections virology, Human T-lymphotropic virus 1 isolation & purification, Humans, Leukemia-Lymphoma, Adult T-Cell genetics, Leukemia-Lymphoma, Adult T-Cell metabolism, Leukemia-Lymphoma, Adult T-Cell therapy, Leukemia-Lymphoma, Adult T-Cell virology, Male, Middle Aged, Missouri, Predictive Value of Tests, Retrospective Studies, Tertiary Care Centers, Time Factors, Treatment Outcome, Central Nervous System Neoplasms pathology, HTLV-I Infections pathology, Leukemia-Lymphoma, Adult T-Cell pathology
- Abstract
Human T-cell lymphotropic virus type 1 is associated with adult T-cell leukemia/lymphoma (ATLL). Published series of ATLLs seen at a United States medical institution are rare. We present the features of 4 ATLLs diagnosed at our North American tertiary care medical center from 1990 to 2012. Despite the absence of a history of origin from an endemic region, all our ATLLs demonstrated evidence of human T-cell lymphotropic virus type 1 infection. Central nervous system (CNS) involvement by ATLL was uncommon in our series, and represented only 1.6% (1/64) of all CNS B-cell or T-cell lymphomas diagnosed over a 20+ year period at our institution. Review of the medical literature reveals that the majority of CNS-involved ATLLs present with the lymphoma or acute subtype, and complete remission is difficult to achieve in these cases. CNS involvement frequently occurs with a systemic disease, which carries an aggressive clinical course with poor prognosis. In addition, CNS involvement by ATLL can be the initial presentation or seen with relapsed disease, can be the only site or be associated with other tissue sites of involvement, and may manifest with variable clinical signs/symptoms. Our retrospective study reveals that ATLLs are rare mature T-cell lymphomas in a native North American population, but the clinical and histopathologic features of ATLLs from this nonendemic region are similar to those seen from other endemic regions. Early recognition of these rare ATLLs involving uncommon sites, such as the CNS, will help optimize treatment for these infrequent mature T-cell lymphomas.
- Published
- 2014
- Full Text
- View/download PDF
9. Anaplastic large-cell lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary.
- Author
-
Nguyen TT, Kreisel FH, Frater JL, and Bartlett NL
- Subjects
- Carcinoma metabolism, Carcinoma secondary, Diagnosis, Differential, Female, Humans, Immunohistochemistry, Lymphoma, Large-Cell, Anaplastic metabolism, Middle Aged, Neoplasms, Unknown Primary metabolism, Neoplasms, Unknown Primary pathology, Carcinoma diagnosis, Keratins metabolism, Lymphoma, Large-Cell, Anaplastic diagnosis, Neoplasms, Unknown Primary diagnosis
- Published
- 2013
- Full Text
- View/download PDF
10. Cutaneous myeloid sarcoma: natural history and biology of an uncommon manifestation of acute myeloid leukemia.
- Author
-
Hurley MY, Ghahramani GK, Frisch S, Armbrecht ES, Lind AC, Nguyen TT, Hassan A, Kreisel FH, and Frater JL
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Analysis of Variance, Antineoplastic Agents therapeutic use, Biopsy, Bone Marrow Examination, Chi-Square Distribution, Child, Child, Preschool, Female, Flow Cytometry, Humans, Immunohistochemistry, Infant, Infant, Newborn, Karyotyping, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute pathology, Male, Middle Aged, Missouri, Predictive Value of Tests, Retrospective Studies, Sarcoma, Myeloid drug therapy, Sarcoma, Myeloid genetics, Sarcoma, Myeloid mortality, Sarcoma, Myeloid pathology, Skin Neoplasms drug therapy, Skin Neoplasms genetics, Skin Neoplasms mortality, Skin Neoplasms pathology, Tertiary Care Centers, Time Factors, Treatment Outcome, Young Adult, Leukemia, Myeloid, Acute diagnosis, Sarcoma, Myeloid diagnosis, Skin pathology, Skin Neoplasms diagnosis
- Abstract
We conducted a retrospective study of patients with cutaneous myeloid sarcoma, from 2 tertiary care institutions. Eighty-three patients presented, with a mean age of 52 years. Diagnosis of myeloid sarcoma in the skin was difficult due to the low frequency of myeloperoxidase and/or CD34+ cases (56% and 19% of tested cases, respectively). Seventy-one of the 83 patients (86%) had ≥ 1 bone marrow biopsy. Twenty-eight (39%) had acute myeloid leukemia with monocytic differentiation. Twenty-three had other de novo acute myeloid leukemia subtypes. Thirteen patients had other myeloid neoplasms, of which 4 ultimately progressed to an acute myeloid leukemia. Seven had no bone marrow malignancy. Ninety-eight percent of the patients received chemotherapy, and approximately 89% died of causes related to their disease. Cutaneous myeloid sarcoma in most cases represents an aggressive manifestation of acute myeloid leukemia. Diagnosis can be challenging due to lack of myeloblast-associated antigen expression in many cases, and difficulty in distinguishing monocyte-lineage blasts from neoplastic and non-neoplastic mature monocytes.
- Published
- 2013
- Full Text
- View/download PDF
11. Assessment of cellular proliferation in tumors by PET using 18F-ISO-1.
- Author
-
Dehdashti F, Laforest R, Gao F, Shoghi KI, Aft RL, Nussenbaum B, Kreisel FH, Bartlett NL, Cashen A, Wagner-Johnston N, and Mach RH
- Subjects
- Adult, Aged, Aged, 80 and over, Benzamides, Female, Fluorine Radioisotopes, Humans, Ki-67 Antigen metabolism, Male, Middle Aged, Mitotic Index, Radiation Dosage, Radiopharmaceuticals, Breast Neoplasms diagnostic imaging, Breast Neoplasms pathology, Cell Proliferation, Head and Neck Neoplasms diagnostic imaging, Head and Neck Neoplasms pathology, Lymphoma diagnostic imaging, Lymphoma pathology, Positron-Emission Tomography
- Abstract
Unlabelled: This first study in humans was designed to evaluate the safety and dosimetry of a cellular proliferative marker, N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-(18)F-fluoroethoxy)-5-methylbenzamide ((18)F-ISO-1), and evaluate the feasibility of imaging tumor proliferation by PET in patients with newly diagnosed malignant neoplasms., Methods: Patients with biopsy-proven lymphoma, breast cancer, or head and neck cancer underwent (18)F-ISO-1 PET. Tumor (18)F-ISO-1 uptake was assessed semiquantitatively by maximum standardized uptake value, ratios of tumor to normal tissue and tumor to muscle, and relative distribution volume ratio. The PET results were correlated with tumor Ki-67 and mitotic index, from in vitro assays of the tumor tissue. The biodistribution of (18)F-ISO-1 and human dosimetry were evaluated., Results: Thirty patients with primary breast cancer (n = 13), head and neck cancer (n = 10), and lymphoma (n = 7) were evaluated. In the entire group, tumor maximum standardized uptake value and tumor-to-muscle ratio correlated significantly with Ki-67 (τ = 0.27, P = 0.04, and τ = 0.38, P = 0.003, respectively), but no significant correlation was observed between Ki-67 and tumor-to-normal-tissue ratio (τ = 0.07, P = 0.56) or distribution volume ratio (τ = 0.26, P = 0.14). On the basis of whole-body PET data, the gallbladder is the dose-limiting organ, with an average radiation dose of 0.091 mGy/MBq. The whole-body and effective doses were 0.012 mGy/MBq and 0.016 mSv/MBq, respectively. No adverse effects of (18)F-ISO-1 were encountered., Conclusion: The presence of a significant correlation between (18)F-ISO-1 and Ki-67 makes this agent promising for evaluation of the proliferative status of solid tumors. The relatively small absorbed doses to normal organs allow for the safe administration of up to 550 MBq, which is sufficient for PET imaging in clinical trials.
- Published
- 2013
- Full Text
- View/download PDF
12. Use of a United States-based laboratory as a hematopathology reference center for a developing country: logistics and results.
- Author
-
Deetz CO, Scott MG, Ladenson JH, Seyoum M, Hassan A, Kreisel FH, Nguyen TT, and Frater JL
- Subjects
- Aircraft, Bone Marrow pathology, Developed Countries, Developing Countries, Eritrea, Health Care Costs, Hematologic Neoplasms blood, Hematologic Neoplasms pathology, Hematology economics, Hematology methods, Hematology organization & administration, Humans, Infectious Disease Medicine economics, Infectious Disease Medicine methods, Infectious Disease Medicine organization & administration, International Agencies, Leishmaniasis blood, Leishmaniasis parasitology, Leishmaniasis pathology, Medical Oncology economics, Medical Oncology methods, Medical Oncology organization & administration, Pathology, Clinical economics, Pathology, Clinical methods, Pathology, Clinical organization & administration, Specimen Handling, Telecommunications, Time Factors, United States, Voluntary Health Agencies, Bone Marrow Examination economics, Bone Marrow Examination standards, Hematologic Neoplasms diagnosis, Hematologic Tests economics, Hematologic Tests standards, International Cooperation, Leishmaniasis diagnosis
- Abstract
Introduction: With proper logistical support and sponsorship, a laboratory in an industrialized nation might be able to act as a reference laboratory for clinicians based in a developing country., Methods: We built on previous experience in the clinical laboratory to see whether a specialized histopathology service (hematopathology) could be provided to a developing country without the expertise or experience to do it in country., Results: Over an 13-year period, 582 cases from 579 individuals were analyzed. Principal pathologic findings included acute leukemia in 84 cases (14%), dyspoiesis in one or more of the hematopoietic lineages in 65 cases (11%, including three cases with high-grade myelodysplasia), 23 cases (4%) with findings suspicious for a chronic myeloproliferative disorder, 35 cases (6%) with findings suspicious for a lymphoproliferative disorder, and infectious organisms (presumably Leishmania in most instances) in 9 (1%) of cases. Specimens from 45 cases (8%) were unsatisfactory owing to extreme hemodilution and/or specimen degeneration., Conclusion: With proper support, a medical laboratory in an industrialized nation may serve as a reference facility for a developing nation. The use of existing infrastructure may be remarkably effective to achieve optimal turnaround time. Although the lack of ancillary studies and follow-up biopsies limit the ability to achieve a definitive diagnosis in many cases, this must be viewed in the context of the limited ability to diagnose or manage hematopoietic neoplasia in developing nations., (© 2012 Blackwell Publishing Ltd.)
- Published
- 2013
- Full Text
- View/download PDF
13. MIST1-a novel marker of plasmacytic differentiation.
- Author
-
Yeung CC, Mills JC, Hassan A, Kreisel FH, Nguyen TT, and Frater JL
- Subjects
- ADP-ribosyl Cyclase 1 metabolism, Flow Cytometry, Humans, Immunohistochemistry, Lymphoma classification, Lymphoma metabolism, Syndecan-1 metabolism, Basic Helix-Loop-Helix Transcription Factors metabolism, Biomarkers, Tumor metabolism, Cell Differentiation, Lymphoma pathology, Plasma Cells cytology
- Abstract
Background: Currently available plasma cell markers include CD138 and CD38. However, CD38 is not specific to plasma cells. It is also expressed by many epithelial cells and other hematopoietic cells. In addition, rare CD138-negative PCNs may be exceedingly difficult to diagnose. MIST1 is a transcription factor expressed by mouse and human neoplastic and non-neoplastic plasma cells. Our goals were to compare MIST1 expression to CD38/CD138 in neoplasms with plasmacytic differentiation, assess reactivity in normal samples and nonplasmacytic cell lineages, and to determine whether MIST1 is expressed in CD138-negative PCNs., Design: Eighty-five neoplasms with plasma cell differentiation [marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), plasmablastic lymphoma (PB), plasma cell neoplasm (PCN)] and 2 non-neoplastic cases (normal marrow) were tested with MIST1 immunohistochemistry. CD138/38 expression for each case was compared with MIST1 reactivity., Results: Plasma cells were MIST1 positive in all cases interrogated. CD38 and/or CD138 expression was reviewed in all cases and found to be concordant in 46/47 (97.8%) of tested cases, with the exception of 1 case of PB that showed MIST1 positivity and no CD138 expression. All other cell lineages were negative, with the exception of MZL and LPL, in which MIST1 highlighted a subset of the lymphocytes, with plasmacytic differentiation., Conclusions: MIST1 is a sensitive and specific marker of plasmacytic differentiation. CD138+ plasma cells expressed MIST1 in all tested cases; however, 1 PB showed MIST1 positivity and no CD138 expression, suggesting MIST1 may be useful in certain CD138-negative cases. In MZL and LPL, MIST1 highlights a subset of the lymphocytes in lymphomas with plasmacytic differentiation.
- Published
- 2012
- Full Text
- View/download PDF
14. State of the art in myeloid sarcoma.
- Author
-
Klco JM, Welch JS, Nguyen TT, Hurley MY, Kreisel FH, Hassan A, Lind AC, and Frater JL
- Subjects
- Antigens, CD analysis, Antigens, CD34 analysis, Antigens, Differentiation, Myelomonocytic analysis, Child, Diagnosis, Differential, Humans, Immunohistochemistry, Proto-Oncogene Proteins c-kit analysis, Sarcoma, Myeloid diagnosis, Sialic Acid Binding Ig-like Lectin 3, Biomarkers, Tumor analysis, Chromosome Aberrations, Sarcoma, Myeloid genetics, Sarcoma, Myeloid metabolism
- Abstract
Introduction: Myeloid sarcomas are extramedullary lesions composed of myeloid lineage blasts that typically form tumorous masses and may precede, follow, or occur in the absence of systemic acute myeloid leukemia. They most commonly involve the skin and soft tissues, lymph nodes, and gastrointestinal tract and are particularly challenging to diagnose in patients without an antecedent history of acute myeloid leukemia., Methods: We conducted a search of the English language medical literature for recent studies of interest to individuals involved in the diagnosis of myeloid sarcoma., Results: The differential diagnosis includes non-Hodgkin lymphoma, blastic plasmacytoid dendritic cell neoplasm, histiocytic sarcoma, melanoma, carcinoma, and (in children) small round blue cell tumors. The sensitivity and specificity of immunohistochemical markers must be considered when evaluating a suspected case of myeloid sarcoma. A high percentage of tested cases have cytogenetic abnormalities., Conclusion: A minimal panel of immunohistochemical markers should include anti-CD43 or anti-lysozyme as a lack of immunoreactivity for either of these sensitive markers would be inconsistent with a diagnosis of myeloid sarcoma. Use of more specific markers of myeloid disease, such as CD33, myeloperoxidase, CD34 and CD117 is necessary to establish the diagnosis. Other antibodies may be added depending on the differential diagnosis. Identification of acute myeloid leukemia-associated genetic lesions may be helpful in arriving at the correct diagnosis., (© 2011 Blackwell Publishing Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
15. Use of classic and novel immunohistochemical markers in the diagnosis of cutaneous myeloid sarcoma.
- Author
-
Amador-Ortiz C, Hurley MY, Ghahramani GK, Frisch S, Klco JM, Lind AC, Nguyen TT, Hassan A, Kreisel FH, and Frater JL
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Diagnosis, Differential, Female, Humans, Infant, Kruppel-Like Factor 4, Male, Middle Aged, Biomarkers, Tumor metabolism, Neoplasm Proteins metabolism, Sarcoma, Myeloid metabolism, Sarcoma, Myeloid pathology, Skin Neoplasms metabolism, Skin Neoplasms pathology
- Abstract
Cutaneous myeloid sarcoma is often challenging to diagnose based solely upon histopathological features. Although immunohistochemistry can aid in its diagnosis, specific markers have not been clearly identified. We evaluated the utility of immunohistochemical markers in 57 cutaneous myeloid sarcoma cases. In addition to classical markers (CD117, CD163, CD34, myeloperoxidase and lysozyme), we used CD33 and CD14, recently described markers in paraffin-embedded tissue samples, and Kruppel-like factor 4 (KLF-4), a novel monocytic marker. Our results show that lysozyme was expressed in 91%, CD33 in 60%, myeloperoxidase in 54%, CD34 in 39% and CD117 in 36% of cases. An antibody panel that included lysozyme, CD117 and CD33 identified all cases. The monocytic markers CD14, KLF-4 and CD163 were expressed in 60, 58 and 40% of all cases, respectively. CD14 and KLF-4 expression was significantly more common in cases with monocytic differentiation. CD14 is the single most sensitive and specific marker for monocytic differentiation (79 and 80%). Although KLF-4 in isolation is relatively insensitive (50 and 87%), it enhances sensitivity in detecting monocytic cutaneous myeloid sarcoma when combined with CD14. Our results indicate that in addition to classical immunohistochemical markers, targeted use of newer antibodies, including CD33, CD14 and KLF-4 is useful in the diagnosis of cutaneous myeloid sarcoma and in the detection of monocytic differentiation., (Copyright © 2011 John Wiley & Sons A/S.)
- Published
- 2011
- Full Text
- View/download PDF
16. Immunohistochemical analysis of monocytic leukemias: usefulness of CD14 and Kruppel-like factor 4, a novel monocyte marker.
- Author
-
Klco JM, Kulkarni S, Kreisel FH, Nguyen TD, Hassan A, and Frater JL
- Subjects
- Antigens, CD biosynthesis, Antigens, CD34 biosynthesis, Antigens, Differentiation, Myelomonocytic analysis, Antigens, Differentiation, Myelomonocytic biosynthesis, Antigens, Differentiation, Myelomonocytic metabolism, Humans, Immunohistochemistry, Kruppel-Like Factor 4, Kruppel-Like Transcription Factors analysis, Lipopolysaccharide Receptors analysis, Monocytes pathology, Receptors, Cell Surface biosynthesis, Biomarkers, Tumor, Kruppel-Like Transcription Factors biosynthesis, Leukemia, Monocytic, Acute metabolism, Leukemia, Monocytic, Acute pathology, Leukemia, Myeloid metabolism, Leukemia, Myeloid pathology, Lipopolysaccharide Receptors biosynthesis
- Abstract
Detection of monocytic differentiation in myeloid neoplasms by immunohistochemical analysis is challenging owing to a lack of sensitive and/or specific antibodies. We tested the usefulness of immunohistochemical analysis for CD14, an antigen commonly detected by flow cytometry, and Krüppel-like factor 4 (KLF4), a potentially novel marker of monocytic differentiation, in a series of myeloid leukemias, including 53 acute myeloid leukemias with monocytic differentiation. These findings were compared with immunohistochemical findings for CD68 (KP-1), CD34, and CD163 and were also correlated with flow cytometric and enzyme cytochemical results. CD163 and CD14 are the most specific markers of monocytic differentiation, followed by KLF4. CD68, in contrast, is the most sensitive monocytic marker, and KLF4 is also significantly more sensitive than CD14 and CD163. These studies show that KLF4 is another marker of monocytic differentiation and that the combination of CD14 and CD163 can increase the diagnostic sensitivity for monocytic neoplasms.
- Published
- 2011
- Full Text
- View/download PDF
17. Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease.
- Author
-
Krishnamurthy S, Hassan A, Frater JL, Paessler ME, and Kreisel FH
- Subjects
- Adolescent, Adult, B-Lymphocytes immunology, B-Lymphocytes metabolism, Biomarkers, Tumor metabolism, Child, Child, Preschool, Fatal Outcome, Female, Hodgkin Disease etiology, Hodgkin Disease metabolism, Humans, Immunocompromised Host, Immunosuppression Therapy, Immunosuppressive Agents adverse effects, Lymphoproliferative Disorders etiology, Lymphoproliferative Disorders metabolism, Male, Middle Aged, Postoperative Complications, RNA-Binding Proteins metabolism, Reed-Sternberg Cells metabolism, Reed-Sternberg Cells pathology, Ribosomal Proteins metabolism, B-Lymphocytes pathology, Hodgkin Disease pathology, Lymphoproliferative Disorders pathology, Organ Transplantation adverse effects
- Abstract
Because of its rarity, pathologic and clinical features of Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) are not well understood, and it is unclear whether its biological behavior is more closely related to classical Hodgkin disease or to monomorphic B-cell PTLD. The authors compared 6 cases of HL-like PTLD with 5 cases of monomorphic B-cell PTLD for differences in histology, immunophenotype, and clinical behavior. Histologically, all cases of HL-like PTLD resembled classical HL with typical Reed-Sternberg (RS) cells and a cellular background mimicking mixed cellularity subtype. CD45 was absent on RS-like cells, but the expression pattern of B-cell-associated markers Oct-2 and BOB.1 resembled monomorphic B-cell PTLD. Whereas Epstein-Barr virus early RNA expression is normally restricted to RS cells of classical HL, it was expressed in both RS-like cells and background lymphocytes in HL-like PTLD. Although all patients diagnosed with monomorphic B-cell PTLD show no evidence of disease following treatment, half of the patients with HL-like PTLD relapsed or died, indicating a more aggressive clinical behavior. The findings suggest that HL-like PTLD represents a distinct clinicopathologic entity with an aggressive clinical course.
- Published
- 2010
- Full Text
- View/download PDF
18. CCR2 regulates monocyte recruitment as well as CD4 T1 allorecognition after lung transplantation.
- Author
-
Gelman AE, Okazaki M, Sugimoto S, Li W, Kornfeld CG, Lai J, Richardson SB, Kreisel FH, Huang HJ, Tietjens JR, Zinselmeyer BH, Patterson GA, Miller MJ, Krupnick AS, and Kreisel D
- Subjects
- Animals, Chemokines, Graft Rejection immunology, Inflammation, Lymphocyte Count, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, Pneumonia metabolism, T-Lymphocytes metabolism, Transplantation, Homologous, Lung Transplantation methods, Monocytes immunology, Monocytes metabolism, Monocytes physiology
- Abstract
Graft rejection remains a formidable problem contributing to poor outcomes after lung transplantation. Blocking chemokine pathways have yielded promising results in some organ transplant systems. Previous clinical studies have demonstrated upregulation of CCR2 ligands following lung transplantation. Moreover, lung injury is attenuated in CCR2-deficient mice in several inflammatory models. In this study, we examined the role of CCR2 in monocyte recruitment and alloimmune responses in a mouse model of vascularized orthotopic lung transplantation. The CCR2 ligand MCP-1 is upregulated in serum and allografts following lung transplantation. CCR2 is critical for the mobilization of monocytes from the bone marrow into the bloodstream and for the accumulation of CD11c(+) cells within lung allografts. A portion of graft-infiltrating recipient CD11c(+) cells expresses both recipient and donor MHC molecules. Two-photon imaging demonstrates that recipient CD11c(+) cells are associated with recipient T cells within the graft. While recipient CCR2 deficiency does not prevent acute lung rejection and is associated with increased graft infiltration by T cells, it significantly reduces CD4(+) T(h)1 indirect and direct allorecognition. Thus, CCR2 may be a potential target to attenuate alloimmune responses after lung transplantation.
- Published
- 2010
- Full Text
- View/download PDF
19. Cystic lymphoid hyperplasia of the parotid gland in HIV-positive and HIV-negative patients: quantitative immunopathology.
- Author
-
Kreisel FH, Frater JL, Hassan A, and El-Mofty SK
- Subjects
- Adult, Aged, Antigens, CD analysis, Antigens, CD20 analysis, Antigens, Differentiation, Myelomonocytic analysis, B-Lymphocytes immunology, B-Lymphocytes pathology, CD4-CD8 Ratio, CD57 Antigens analysis, Cysts immunology, Female, HIV Infections immunology, Humans, Hyperplasia, Immunophenotyping, Killer Cells, Natural immunology, Killer Cells, Natural pathology, Leukocyte Common Antigens analysis, Leukocytes immunology, Leukocytes pathology, Lymphocytes immunology, Lymphocytes pathology, Lymphoid Tissue immunology, Macrophages immunology, Macrophages pathology, Male, Middle Aged, Parotid Diseases immunology, Parotitis immunology, Parotitis pathology, Sjogren's Syndrome immunology, Sjogren's Syndrome pathology, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic pathology, T-Lymphocytes, Helper-Inducer immunology, T-Lymphocytes, Helper-Inducer pathology, Cysts pathology, HIV Infections pathology, HIV Seronegativity immunology, Lymphoid Tissue pathology, Parotid Diseases pathology
- Abstract
Background: Benign lymphoepithelial lesions of the parotid include a spectrum of disorders ranging from lymphoepithelial sialadenitis (LESA) of Sjögren syndrome to lymphoepithelial cysts (LEC) and both human immunodeficiency virus (HIV)-related and -unrelated cystic lymphoid hyperplasia (CLH). They share a common microscopic appearance characterized by epimyoepithelial islands and/or epithelial lined cysts in a lymphoid stroma. However, they differ greatly regarding their etiology, clinical presentation, and management., Objective: The purpose of this study was to establish specific immunophenotypic profiles for these diverse disease entities., Study Design: Four cases of HIV+ CLH, 5 cases of HIV- CLH, 3 cases of LESA of Sjögren syndrome, and 3 cases of sporadic LEC were quantitatively analyzed for distribution of lymphoreticular cell subpopulations, using antibodies against CD20, CD45RO, CD4, CD8, CD57, and CD68., Results: The cystic lesions in both the HIV+ and HIV- cases were microscopically analogous. However, a marked decrease in the interfollicular CD4:CD8 ratio was observed in all HIV+ CLH cases, which was statistically significant when compared with the HIV- cases (P = .02) and cases of LESA of Sjögren syndrome (P = .03). No significant differences regarding the distribution of CD20+ B lymphocytes in epithelial cyst lining or the interfollicular or follicular distribution of CD20+, CD45RO+, CD57+, and CD68+ cells were present among the different groups., Conclusion: Analysis of the interfollicular CD4:CD8 ratio may offer a simple immunophenotypic approach in the distinction of HIV+ from other lymphoepithelial lesions of the parotid gland, when HIV status is unknown and p24 immunohistochemistry is not readily available., (Copyright 2010 Mosby, Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
20. Molecular pathology of myeloproliferative neoplasms.
- Author
-
Klco JM, Vij R, Kreisel FH, Hassan A, and Frater JL
- Subjects
- Diagnosis, Differential, Humans, Myeloproliferative Disorders classification, Myeloproliferative Disorders genetics, Signal Transduction genetics, Janus Kinase 2 genetics, Myeloid Progenitor Cells pathology, Myeloproliferative Disorders pathology
- Abstract
Myeloproliferative neoplasms (MPNs; formerly chronic myeloproliferative disorders) are a class of myeloid hematologic malignancies that represent a stem cell-derived expansion of 1 or more hematopoietic cell lineages. The current 2008 World Health Organization system recognizes 8 types of MPN: chronic myelogenous leukemia, chronic neutrophilic leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, chronic eosinophilic leukemia, mastocytosis, and myeloproliferative neoplasm, unclassifiable. This review summarizes the salient characteristics of the MPNs, with emphasis on recent developments in the molecular pathophysiology and therapeutic monitoring of these disorders.
- Published
- 2010
- Full Text
- View/download PDF
21. Bone marrow biopsy in patients with hepatitis C virus infection: spectrum of findings and diagnostic utility.
- Author
-
Klco JM, Geng B, Brunt EM, Hassan A, Nguyen TD, Kreisel FH, Lisker-Melman M, and Frater JL
- Subjects
- Adult, Biopsy, Blood Cell Count, Erythropoiesis, Female, Hepatitis C blood, Hepatitis C complications, Humans, Leukemia, Myeloid, Acute blood, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute etiology, Male, Middle Aged, Myelodysplastic Syndromes blood, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes etiology, Pancytopenia blood, Retrospective Studies, Bone Marrow pathology, Hepacivirus, Hepatitis C pathology, Leukemia, Myeloid, Acute pathology, Myelodysplastic Syndromes pathology, Pancytopenia pathology
- Abstract
Patients with hepatitis C virus (HCV) infection develop a number of hematologic disorders, with benign and malignant B-cell proliferations being the most common. HCV-infected patients are also prone to developing peripheral cytopenias, the etiologies of which are multifactorial and include hypersplenism and/or antiviral medications. Some of these patients may undergo bone marrow biopsy but no study has systematically recorded the bone marrow findings in this patient group. Here, we report on the range of bone marrow findings in 47 adult HCV-infected patients. These patients, who lacked concurrent human immunodefiency virus (HIV) infection, most commonly presented for a bone marrow biopsy due to abnormal peripheral cell counts. The bone marrow biopsies displayed a range of findings. Dyserythropoiesis, present in 19% of the cases, was the most common finding. Patients with pancytopenia(n = 6), as defined by current World Health Organization standards, were the most likely to have bone marrow abnormalities; two pancytopenic patients had acute myeloid leukemia, and one patient had a primary myelodysplastic syndrome. There was no correlation in bone marrow findings and antiviral medications, MELD score, cirrhosis or splenomegaly, suggesting that the degree of bone marrow dysfunction is independent of stage of HCV. The results of this study suggest that bone marrow biopsy in HCV-infected patients, even those with features of hypersplenism and/or documented antiviral therapy, can be a valid test for hematologic evaluation, especially for patients with severe pancytopenia and/or sudden alterations in peripheral cell counts.
- Published
- 2010
- Full Text
- View/download PDF
22. Cutting edge: Acute lung allograft rejection is independent of secondary lymphoid organs.
- Author
-
Gelman AE, Li W, Richardson SB, Zinselmeyer BH, Lai J, Okazaki M, Kornfeld CG, Kreisel FH, Sugimoto S, Tietjens JR, Dempster J, Patterson GA, Krupnick AS, Miller MJ, and Kreisel D
- Subjects
- Adoptive Transfer, Animals, Immunohistochemistry, Mice, Microscopy, Fluorescence, Transplantation, Homologous, Graft Rejection immunology, Lung Transplantation immunology, Lymphocyte Activation immunology, Lymphoid Tissue immunology, T-Lymphocytes immunology
- Abstract
It is the prevailing view that adaptive immune responses are initiated in secondary lymphoid organs. Studies using alymphoplastic mice have shown that secondary lymphoid organs are essential to initiate allograft rejection of skin, heart, and small bowel. The high immunogenicity of lungs is well recognized and allograft rejection remains a major contributing factor to poor outcomes after lung transplantation. We show in this study that alloreactive T cells are initially primed within lung allografts and not in secondary lymphoid organs following transplantation. In contrast to other organs, lungs are acutely rejected in the absence of secondary lymphoid organs. Two-photon microscopy revealed that recipient T cells cluster predominantly around lung-resident, donor-derived CD11c(+) cells early after engraftment. These findings demonstrate for the first time that alloimmune responses following lung transplantation are initiated in the graft itself and therefore identify a novel, potentially clinically relevant mechanism of lung allograft rejection.
- Published
- 2009
- Full Text
- View/download PDF
23. Costimulatory blockade-mediated lung allograft acceptance is abrogated by overexpression of Bcl-2 in the recipient.
- Author
-
Okazaki M, Sugimoto S, Lai J, Kornfeld CG, Hotchkiss RS, Richardson SB, Li W, Kreisel FH, Huang HJ, Patterson GA, Krupnick AS, Gelman AE, and Kreisel D
- Subjects
- Abatacept, Animals, CD4-Positive T-Lymphocytes immunology, Gene Expression Regulation, Graft Rejection immunology, Immunoconjugates immunology, Lung Transplantation immunology, Lung Transplantation pathology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Lung Transplantation physiology, Proto-Oncogene Proteins c-bcl-2 genetics, Transplantation, Homologous physiology
- Abstract
Lung allografts are considered to be more immunogenic than other solid organs. Little is known about the effectiveness of immunosuppressive regimens after lung transplantation. Herein, we describe a novel model of murine vascularized orthotopic lung transplantation we used to study the effects of costimulatory blockade on lung rejection. Transplants were performed in the Balb --> B6 strain combination. Recipients were either not immunosuppressed or received perioperative CD40/CD40L and CD28/B7 costimulatory blockade. Nonimmunosupressed Balb/c --> B6 lung transplants had severe acute rejection 7 days after transplantation and CD8(+) T cells outnumbered CD4(+) T cells within the allografts. Alternatively, B6 recipients that received perioperative costimulatory blockade had minimal inflammation and there were nearly equal numbers of CD8(+) and CD4(+) T cells in these grafts. Approximately one third of graft-infiltrating CD4(+) T cells expressed Foxp3. CD4(+) T cells isolated from these grafts induced apoptosis of alloreactive CD8(+) T cells that were stimulated with donor splenocytes in vitro. In contrast with wild-type B6 recipient mice, we observed severe rejection of Balb/c lungs 7 days after transplantation into Bcl-2 transgenic B6 recipients that had received costimulatory blockade. CD8(+) T cells outnumbered CD4(+) T cells in these immunosuppressed Bcl-2 transgenic recipients and, compared with immunosuppressed wild-type B6 recipients, a lower percentage of graft-infiltrating CD4(+) T cells expressed Foxp3, and a higher percentage of graft-infiltrating CD8(+) T cells expressed intereferon-gamma. Thus, our results show that perioperative blockade of the CD40/CD40L and CD28/B7 costimulatory pathways markedly ameliorates acute rejection of lung allografts in wild type but not Bcl-2 transgenic recipients.
- Published
- 2009
- Full Text
- View/download PDF
24. The spectrum of adult B-lymphoid leukemias with BCR-ABL: molecular diagnostic, cytogenetic, and clinical laboratory perspectives.
- Author
-
Klco JM, Kreisel FH, Zehnbauer BA, Kulkarni S, Hassan A, and Frater JL
- Subjects
- Adolescent, Adult, Aged, Blast Crisis pathology, Cohort Studies, Cytogenetic Analysis, Female, Humans, Immunophenotyping, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Retrospective Studies, Young Adult, Blast Crisis genetics, Fusion Proteins, bcr-abl genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics
- Abstract
The Philadelphia (Ph) chromosome is characteristic of chronic myelogenous leukemia (CML), but it is also the most frequent cytogenetic abnormality in precursor B-lymphoblastic leukemia (ALL) of adults. The vast majority of CML patients have a BCR-ABL translocation that yields a 210 kD (p210) oncoprotein, whereas adult Ph-positive ALL cases can present with either a p190 or a p210 oncoprotein, or both. Considering that 30% of the patients with CML that progress to blast crisis will have a lymphoblastic presentation, adults presenting with a p210 ALL may have either a de novo ALL or CML presenting for the first time in lymphoblastic phase. To identify the distinguishing features, cases of p190-ALL, p210-ALL, and lymphoblastic CML were compared. In spite of significant overlap between the three entities, a number of features were found to aid in their differentiation. p210-ALL patients present at a younger age with blasts that frequently show loss of expression of CD34, whereas p190-ALL patients present with marked increase in peripheral blast percentage. Interestingly, bone marrow findings characteristic of a myeloproliferative disorder are specific, but are not sensitive for lymphoblastic CML. This study suggests that despite the similarities between these leukemias, p190-ALL, p210-ALL, and lymphoblastic phase CML likely represent three distinct diseases., (Copyright 2008 Wiley-Liss, Inc.)
- Published
- 2008
- Full Text
- View/download PDF
25. Secondary lymphoma involving metastatic follicular thyroid carcinoma to the skull: a unique example of tumor-to-tumor metastasis.
- Author
-
Lu J, Frater JL, Kreisel FH, Marcus JN, and Hassan A
- Subjects
- Adenocarcinoma, Follicular therapy, Combined Modality Therapy, Female, Humans, Lymphoma therapy, Middle Aged, Neoplasm Metastasis, Neoplasms, Second Primary therapy, Salvage Therapy, Thyroid Neoplasms therapy, Adenocarcinoma, Follicular secondary, Lymphoma pathology, Neoplasms, Second Primary pathology, Thyroid Neoplasms pathology
- Abstract
Tumor-to-tumor metastases to the skull, presenting as a scalp mass, and thyroid follicular carcinoma presenting in that location are extremely rare. We present the case of a patient with recently diagnosed retroperitoneal diffuse large B-cell lymphoma and an 8-year history of a non-tender large scalp-based mass. The scalp mass was an osteolytic enhancing lesion on imaging studies and diagnosed as metastatic thyroid carcinoma to the skull. The patient had no pre-existing history of thyroid cancer. This metastatic carcinoma was also secondarily involved with diffuse large B-cell lymphoma. This case illustrates a unique and previously unreported example of tumor-to-tumor metastasis in which both malignancies represent metastatic tumors to the skull with soft tissue extension presenting as a large scalp mass.
- Published
- 2008
- Full Text
- View/download PDF
26. CD4+ T lymphocytes are not necessary for the acute rejection of vascularized mouse lung transplants.
- Author
-
Gelman AE, Okazaki M, Lai J, Kornfeld CG, Kreisel FH, Richardson SB, Sugimoto S, Tietjens JR, Patterson GA, Krupnick AS, and Kreisel D
- Subjects
- Acute Disease, Animals, Antigen-Presenting Cells cytology, Antigen-Presenting Cells immunology, Autoantigens immunology, B7-1 Antigen immunology, CD28 Antigens immunology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Hematopoiesis immunology, Lung Transplantation pathology, Male, Mice, Transplantation, Homologous immunology, Graft Rejection immunology, Lung Transplantation immunology, Neovascularization, Physiologic
- Abstract
Acute rejection continues to present a major obstacle to successful lung transplantation. Although CD4(+) T lymphocytes are critical for the rejection of some solid organ grafts, the role of CD4(+) T cells in the rejection of lung allografts is largely unknown. In this study, we demonstrate in a novel model of orthotopic vascularized mouse lung transplantation that acute rejection of lung allografts is independent of CD4(+) T cell-mediated allorecognition pathways. CD4(+) T cell-independent rejection occurs in the absence of donor-derived graft-resident hematopoietic APCs. Furthermore, blockade of the CD28/B7 costimulatory pathways attenuates acute lung allograft rejection in the absence of CD4(+) T cells, but does not delay acute rejection when CD4(+) T cells are present. Our results provide new mechanistic insight into the acute rejection of lung allografts and highlight the importance of identifying differences in pathways that regulate the rejection of various organs.
- Published
- 2008
- Full Text
- View/download PDF
27. Interferon-producing cells develop from murine CD31(high)/Ly6C(-) marrow progenitors.
- Author
-
Kreisel FH, Blasius A, Kreisel D, Colonna M, and Cella M
- Subjects
- Animals, Bone Marrow Cells drug effects, Cell Differentiation, Cell Shape drug effects, Cells, Cultured, Membrane Proteins pharmacology, Mice, Phenotype, Antigens, Ly immunology, Bone Marrow Cells cytology, Bone Marrow Cells immunology, Interferons biosynthesis, Platelet Endothelial Cell Adhesion Molecule-1 immunology, Stem Cells cytology, Stem Cells immunology
- Abstract
In this study, we sorted total bone marrow (BM) into six distinct subsets based on surface expression of CD31 and Ly6C and investigated the capacity of these subsets to acquire characteristics of plasmacytoid dendritic cells (PDCs) after in vitro culture with FMS-like tyrosine kinase 3 ligand (Flt3-L). Cultured CD31(high)/Ly6C(-) cells were the only subset that consistently developed immunophenotypic, functional, and morphologic characteristics of PDCs. Culture of this subset resulted in expression of CD11c, B220, and the PDC-specific marker 440C and secretion of interferon-alpha (IFN-alpha) when stimulated with CPG ODN 2216. Cultured cells displayed the typical plasmacytoid morphology of PDCs with eccentrically located nucleus and mature lymphoid chromatin. Unlike conventional dendritic cells (CDCs) that can be generated from CD31(high)/Ly6C(-), CD31(+)/Ly6C(+), and CD31(-)/Ly6C(high) BM subpopulations, PDCs can only be derived from the CD31(high)/Ly6C(-) subset, the subset that reportedly contains the highest frequency of early and late cobblestone area forming cells (CAFC).
- Published
- 2006
- Full Text
- View/download PDF
28. Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells.
- Author
-
Krupnick AS, Gelman AE, Barchet W, Richardson S, Kreisel FH, Turka LA, Colonna M, Patterson GA, and Kreisel D
- Subjects
- Animals, CD4-Positive T-Lymphocytes metabolism, Coculture Techniques, Forkhead Transcription Factors metabolism, Lymphocyte Activation, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Inbred CBA, Mice, Knockout, Receptors, Interleukin-2 metabolism, T-Lymphocyte Subsets metabolism, Transplantation, Homologous, CD4-Positive T-Lymphocytes immunology, Endothelium, Vascular immunology, T-Lymphocyte Subsets immunology
- Abstract
Unlike graft-resident donor-derived hemopoietic APCs, which decrease in number over time after transplantation, vascular endothelial cells are lifelong residents of a vascularized allograft. Endothelial cells are potent APCs for allogeneic CD8+ T lymphocytes but are unable to induce proliferation of allogeneic CD4+ T lymphocytes. Although the reason for this differential response has been poorly understood, here we report that alloantigen presentation by vascular endothelium to CD4+ T lymphocytes activates and induces CD4+25+Foxp3+ regulatory T cells, which can inhibit proliferation of alloreactive T cells both in vitro and in vivo. This process occurs independently of B7.1 costimulation but is dependent on programmed death ligand 1 (B7-H1). This finding may have important implications for tolerance induction in transplantation.
- Published
- 2005
- Full Text
- View/download PDF
29. Bartonella species-induced prosthetic valve endocarditis associated with rapid progression of valvular stenosis.
- Author
-
Kreisel D, Pasque MK, Damiano RJ Jr, Medoff G, Kates A, Kreisel FH, and Lawton JS
- Subjects
- Adult, Aged, Aortic Valve Stenosis microbiology, Aortic Valve Stenosis surgery, Disease Progression, Fatal Outcome, Heart Valve Prosthesis Implantation, Humans, Male, Mitral Valve Stenosis microbiology, Mitral Valve Stenosis surgery, Prosthesis-Related Infections surgery, Reoperation, Treatment Outcome, Bartonella Infections complications, Endocarditis, Bacterial microbiology, Heart Valve Prosthesis microbiology, Prosthesis-Related Infections microbiology
- Published
- 2005
- Full Text
- View/download PDF
30. Pathologic quiz case: a 39-year-old man with severe lower back pain. Plasma cell leukemia.
- Author
-
Castellano-Sanchez AA and Kreisel FH
- Subjects
- Adult, Humans, Male, Leukemia, Plasma Cell complications, Low Back Pain etiology, Pain, Intractable etiology
- Published
- 2005
- Full Text
- View/download PDF
31. Can we rely on pathologic parameters to define conservative treatment of papillary thyroid carcinoma?
- Author
-
Paessler M, Kreisel FH, LiVolsi VA, Akslen LA, and Baloch ZW
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Papillary secondary, Child, Female, Humans, Lymph Nodes pathology, Male, Middle Aged, Neoplasm Invasiveness, Neoplasms, Multiple Primary, Retrospective Studies, Thyroid Neoplasms pathology, Thyroidectomy, Carcinoma, Papillary surgery, Thyroid Neoplasms surgery
- Abstract
Papillary thyroid carcinoma is the most common malignant tumor of the thyroid and usually behaves in an indolent fashion. At most institutions these tumors are treated by near-total or total thyroidectomy followed by radioactive iodine ablation. The 2 main reasons for this extensive treatment include high rate of multicentricity in papillary carcinoma and difficulty in ablating large thyroid remnants with radioactive iodine after partial thyroidectomy. Some authors believe, however, that this treatment protocol may not be justified in all cases of papillary carcinoma. We analyzed 253 total thyroidectomies performed for papillary thyroid carcinoma for the following pathologic variables: tumor size, presence of tumor capsular and/or vascular invasion, intrathyroidal spread, tumor in the contralateral lobe, and lymph node metastases. Tumors measuring less than 1 cm and those with extrathyroidal soft tissue extension were excluded from this study. Among 253 cases (197 females, 56 males, age range 14-88 years), the primary tumor size ranged from 1-9.5 cm; 162 cases were completely encapsulated. Tumor capsule invasion was seen in 139 (86%) and vascular invasion was present in 32 (13%) cases; of these 27 (11% of the total) patients showed both tumor capsule and vascular invasion. Seventy-four (29%) patients showed tumor in the contralateral lobe; in 35 (47%) of these cases the contralateral tumor measured less than 1.0 cm. Lymph nodes were sampled in 106 cases, metastases were present in 67 (67/106 = 63%) and only 16 cases with lymph node metastases showed contralateral tumors. No significant correlation was noted between tumor size, occurrence of contralateral tumors, and lymph node metastases. Seventy-one percent of cases included in this study failed to show contralateral tumors. Hence, pathologic parameters such as lack of vascular invasion and lack of multifocality may be used to identify patients who can benefit from conservative therapy alone.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.